A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

作者：Proietto J^*; Rissanen A; Harp J B; Erondu N; Yu Q; Suryawanshi S; Jones M E; Johnson Levonas A O; Heymsfield S B; Kaufman K D; Amatruda J M

来源：International Journal of Obesity, 2010, 34(8): 1243-1254.

DOI：10.1038/ijo.2010.38

• randomized clinical trial
• cannabinoid-1 receptor
• endocannabinoid

Objective: To evaluate the weight loss efficacy, safety and tolerability of taranabant, a CB1R inverse agonist, in obese and overweight patients.
Design: Multicenter, double-blind, randomized, placebo-controlled study.
Subjects: Patients >= 18 years old, BMI 27-43 kg m(-2), were randomized to placebo (n = 209) or taranabant 0.5 mg (n = 207), 1 mg (n = 208) or 2 mg given orally once daily (n = 417) for 52 weeks.
Measurements: Key efficacy measurements included body weight (BW), waist circumference (WC), lipid endpoints and glycemic endpoints.
Results: Based on a last observation carried forward analysis of the all-patients-treated population, mean change in BW for taranabant 0.5, 1, and 2 mg and placebo was -5.4, -5.3, -6.7 and -1.7 kg, respectively (P<0.001 for all doses vs placebo). The proportions of patients who lost at least 5 and 10% of their baseline BW at week 52 were significantly higher for all taranabant doses vs placebo (P<0.001 for all doses). Reductions in WC, percentage of body fat, and triglycerides were significant for taranabant 2 mg and in triglycerides for taranabant 1 mg vs placebo. There was no effect of taranabant vs placebo on other lipid or glucose-related endpoints. Incidences of adverse experiences classified in the gastrointestinal (diarrhea and nausea), nervous system (dizziness/dizziness postural), psychiatric-related (irritability and anger/aggression) and vascular (flushing/hot flush) organ systems were higher and statistically significant in the taranabant 2-mg group compared with the placebo group. Irritability was higher and statistically significant in all taranabant groups compared with the placebo group.
Conclusion: All three doses of taranabant-induced clinically meaningful and statistically significant weight loss. Incidences of adverse experiences in organ systems known to express CB1R were higher in taranabant groups. International Journal of Obesity (2010) 34, 1243-1254; doi: 10.1038/ijo.2010.38; published online 9 March 2010

• 出版日期2010-8